EP0759976A4 - Isolement et production d'anticorps catalytiques par une technologie faisant appel a des phages - Google Patents

Isolement et production d'anticorps catalytiques par une technologie faisant appel a des phages

Info

Publication number
EP0759976A4
EP0759976A4 EP94919078A EP94919078A EP0759976A4 EP 0759976 A4 EP0759976 A4 EP 0759976A4 EP 94919078 A EP94919078 A EP 94919078A EP 94919078 A EP94919078 A EP 94919078A EP 0759976 A4 EP0759976 A4 EP 0759976A4
Authority
EP
European Patent Office
Prior art keywords
phagentechnology
insulation
production
catalytic antibodies
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94919078A
Other languages
German (de)
English (en)
Other versions
EP0759976A1 (fr
Inventor
Rodger G Smith
John Mccafferty
David Chiswell
Michael J Darsley
Kevin Fitzgerald
John H Kenten
Mark T Martin
Richard C Titmas
Richard O Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGEN International Inc
Original Assignee
IGEN International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGEN International Inc filed Critical IGEN International Inc
Publication of EP0759976A1 publication Critical patent/EP0759976A1/fr
Publication of EP0759976A4 publication Critical patent/EP0759976A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP94919078A 1994-03-30 1994-03-30 Isolement et production d'anticorps catalytiques par une technologie faisant appel a des phages Withdrawn EP0759976A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/003420 WO1995027045A1 (fr) 1994-03-30 1994-03-30 Isolement et production d'anticorps catalytiques par une technologie faisant appel a des phages

Publications (2)

Publication Number Publication Date
EP0759976A1 EP0759976A1 (fr) 1997-03-05
EP0759976A4 true EP0759976A4 (fr) 2001-02-07

Family

ID=22242396

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94919078A Withdrawn EP0759976A4 (fr) 1994-03-30 1994-03-30 Isolement et production d'anticorps catalytiques par une technologie faisant appel a des phages

Country Status (4)

Country Link
EP (1) EP0759976A4 (fr)
JP (1) JPH10507341A (fr)
AU (1) AU695406B2 (fr)
WO (1) WO1995027045A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
CA2334170A1 (fr) 1998-07-27 2000-02-10 Genentech, Inc. Efficacite de transformation amelioree de l'expression a la surface des phages par modification d'une proteine de coque
ES2564161T3 (es) * 2000-07-11 2016-03-18 Research Corporation Technologies, Inc Polipéptidos de anticuerpos artificiales
DE60224720D1 (en) 2001-11-22 2008-03-06 Univ Keio Re
WO2003104418A2 (fr) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Polypeptides reconstitues
FI20022048A0 (fi) 2002-11-18 2002-11-18 Valtion Teknillinen Ei-kompetetiivinen immunomääritys pienille analyyteille
WO2021167952A2 (fr) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Anticorps agonistes dirigés contre l'endogline (eng) et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014430A1 (fr) * 1989-05-16 1990-11-29 Scripps Clinic And Research Foundation Nouveau procede d'exploitation du repertoire immunologique
WO1993012232A1 (fr) * 1991-12-10 1993-06-24 Dana Farber Cancer Institute Anticorps recombine humain anti-gp120 neutralisant le reactif, adn codant celui-ci et son utilisation
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014430A1 (fr) * 1989-05-16 1990-11-29 Scripps Clinic And Research Foundation Nouveau procede d'exploitation du repertoire immunologique
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
WO1993012232A1 (fr) * 1991-12-10 1993-06-24 Dana Farber Cancer Institute Anticorps recombine humain anti-gp120 neutralisant le reactif, adn codant celui-ci et son utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MCCAFFERTY J ET AL: "SELECTION AND RAPID PURIFICATION OF MURINE ANTIBODY FRAGMENTS THAT BIND A TRANSITION-STATE ANALOG BY PHAGE DISPLAY", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY,US,CLIFTON, NJ, vol. 47, 1994, pages 157 - 173, XP002913520, ISSN: 0273-2289 *
See also references of WO9527045A1 *

Also Published As

Publication number Publication date
AU7014194A (en) 1995-10-23
WO1995027045A1 (fr) 1995-10-12
EP0759976A1 (fr) 1997-03-05
AU695406B2 (en) 1998-08-13
JPH10507341A (ja) 1998-07-21

Similar Documents

Publication Publication Date Title
DE69505429D1 (de) Isoliertes Gefäss und Herstellungsverfahren
DE69727162D1 (de) Herstellung von inulinhaltigen Produkten
DE69514950D1 (de) Herstellung von imitierten Kunstwerken
DE69722286D1 (de) Die Herstellung von Zwavel-enthaltende Organosiliziumverbindungen
DE69524215D1 (de) Retroreflektierender körper und herstellungsverfahren
NO975881D0 (no) Katalysator og fremgangsmåte for fremstilling av hydrokarboner
ATE430734T1 (de) Isochinoline und deren herstellung
DE69725326D1 (de) Herstellung von fugizides chinazolinonen und nützliche zwischenprodukte
DE69516689D1 (de) Dehydrierungskatalysator und dehydrierungsverfahren
DE69825253D1 (de) Verfahren für die herstellung von 1,1,1,3,3-pentafluorpropen und 2-chlor-pentafluorpropen
DE69127063D1 (de) Wandlerkopf und Herstellungsverfahren
DE69502384D1 (de) Prozess zur herstellung von polyarylenetherketonen
DE59606486D1 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69330128D1 (de) Poröses polytetrafluorethylen und herstellung
FI963079A7 (fi) Menetelmä prokiraalisten olefiinien epoksidoimiseksi ja siinä käytettävä katalyytti ja välituotteita katalyytin valmistamiseksi
DE69804513D1 (de) Herstellung von zeolith-l
DE69508074D1 (de) Herstellung von porösen körpern
EP0804550A4 (fr) Activation ex vivo des cellules immunes
ATE365805T1 (de) Herstellung von l(+)-lactat
DE69510594D1 (de) Herstellung von magnetostriktiven Material
DE69502912D1 (de) Isomerisierungskatalysator und Isomerisierungsverfahren
DE69502001D1 (de) Herstellung von uranoxid
DE69820310D1 (de) Geträgerter Desodorisierungskatalysator und deren Herstellung
DE69502395D1 (de) Herstellung von triarylboran
DE69509497D1 (de) Herstellung von polyglycerol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961002

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IGEN INTERNATIONAL, INC.

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 9/00 A, 7C 07K 16/00 B, 7A 61K 38/43 B

A4 Supplementary search report drawn up and despatched

Effective date: 20001222

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20011024

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 16/00 B

Ipc: 7C 12N 9/00 A

RTI1 Title (correction)

Free format text: THE ISOLATION AND PRODUCTION OF CATALYTIC ANTIBODIES USING PHAGE TECHNOLOGY

RTI1 Title (correction)

Free format text: ISOLATION AND PRODUCTION OF CATALYTIC ANTIBODIES USING TWO AFFINITY PEPTIDES IN TANDEM

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060308